Cancer & Disease Research
Hope for next-gen COVID-19 vaccines may rest in an unexpected region of the virus
Researchers further elucidated how antibodies produced in people who effectively fight off SARS-CoV-2 work to neutralize the part of the virus responsible for causing infection. The study, published in Science on May 4, describes how antibodies targeting sections of the virus outside of the receptor-binding domain may be useful in the development of vaccines and therapies. Read More
How the South African SARS-CoV-2 variant evades antibodies
Computer modeling has demonstrated that one of the three mutations of the South African SARS-CoV-2 variant reduces its ability to bind to human cells. The results, published recently in the Journal of Medicinal Chemistry, also suggest that the mutation may help it escape some therapeutic antibodies. Read More
Naturally occurring molecule helps SARS-CoV-2 evade neutralizing antibodies
Researchers have identified naturally occurring molecules that are created from the breakdown of hemoglobin and block the binding of a subset of human antibodies to SARS-CoV-2. The discovery, published in Science Advances on April 22, may help explain why some COVID-19 patients can become severely ill despite having high levels of antibodies against the virus. Read More
NIH adds long-acting antibody COVID-19 therapy to ACTIV-3 master protocol
The National Institutes of Health (NIH) has begun a new arm of its master protocol, the Accelerating COVID-19 Therapeutic Interventions and Vaccines 3 (ACTIV-3) study, which evaluates the safety and efficacy of an investigational long-acting antibody combination for the treatment of patients hospitalized with COVID-19. Read More
SARS-CoV-2 mutation doesn't affect viral spread, but may limit therapies
As SARS-CoV-2 spreads around the globe, mutations of the virus are inevitable. An international team of researchers sought to define the effects of a specific receptor-binding motif mutation on viral fitness, clinical outcomes, and resistance to therapeutic antibodies. The findings of the study were published on January 28 in Cell. Read More
2003 SARS-CoV antibodies may provide some protection from SARS-CoV-2
A new study shows that antibodies against the original 2003 SARS-CoV also react with the current SARS-CoV-2 strain, but only with limited effectiveness. The findings were published in Cell Reports on January 25. Read More
What makes immuno-oncology therapies attractive investments?
Although immuno-oncology therapies have been around for many years, investors are excited to partner with innovators in the space who can push the boundaries of what these therapies are able to achieve. A panel of investors and business development executives discussed what exactly makes a specific candidate attractive as a business opportunity during a recorded session at the Biotech Showcase virtual event. Read More
Researchers discover important 2nd SARS-CoV-2 receptor
Researchers have identified a second receptor that might be important in SARS-CoV-2 infectivity, according to a new report published in Science on October 20. This cofactor helps facilitate virus-host cell interactions in cells with low levels of angiotensin-converting enzyme 2, the primary receptor on host cells, and might explain the increased pathogenicity of SARS-CoV-2. Read More
Passive vaccines with mAbs may be effective for COVID-19
Monoclonal antibodies (mAbs) isolated from the blood of recovered COVID-19 patients -- known colloquially as "convalescent plasma" -- could be potentially useful as therapeutic and prophylactic agents for passive vaccination, assuming their administration does not trigger unwanted side effects. The findings of the new study were published in Cell on September 26. Read More
Antibody fragments may be exceptionally effective against SARS-CoV-2
An engineered antibody fragment has been developed as a highly potent neutralizer of SARS-CoV-2. For the first time, one of these tiny molecules has been tested for efficacy in in vitro and in vivo infection models. The results of the collaborative study were published in Cell on September 14. Read More
Connect
Science Advisory Board on LinkedIn
Science Advisory Board on Facebook
Science Advisory Board on Twitter